NCT Number: NCT00913952
To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions
To demonstrate the relative bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride capsules under fed and fasted conditions.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–45 year
Sex eligibility
Male
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion criteria
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Treatment and study plan
Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
DrugBasel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
DrugPrimary outcomes
-
Bioequivalence based on AUC and Cmax
Time frame: 53 days
Sponsors and collaborators
Lead sponsor
Sandoz
Industry
Registry information
Official study title
Comparative, Randomized, 3-way Crossover Bioavailability Study of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules In Health Adult Males Under Fed and Fasted Conditions
Important dates
- Study start
- 1994
- Primary completion
- 1994
- Study completion
- 1994
- First posted
- Jun 4, 2009
- Registry last updated
- Mar 28, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Kintsugi Voice Device Pivotal Study
NCT06809907
Behavior, Behavioral Symptoms
Berkeley, California, United States
View Trial DetailsKintsugi Voice Device Pilot Study
NCT06374056
Behavior, Behavioral Symptoms
Berkeley, California, United States
View Trial DetailsVirtual Reality to Reduce Pre-procedure Anxiety Prior ECT
NCT04291196
Anxiety, Anxiety Disorders
Toronto, Ontario, Canada
View Trial DetailsDyadic Interactions in Depressed and Non-Depressed Mothers and Their Infants
NCT00044174
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial Details